A review of the clinical and safety data on DROPSORDRYTM

*claim on hold

For more information:

tradichem@tradichem.es

Distributed by

An effective ingredient to “support normal urinary function*”

By…

What is UI?

What are the types

of UI?

How is UI treated?

URINARY INCONTINCENCE (UI) IN BRIEF

Urinary incontinence (UI) is a significant health problem defined as a loss of bladder control with symptoms ranging from mild leaking to uncontrollable wetting. This disorder directly affects a person’s

health and quality of life. UI affects more than 200 million people worldwide1.

Incontinence is usually classified into two basic categories2: • Stress urinary incontinence (SUI) SUI is associated to involuntary leakage of urine caused by physical stress (coughing and heavy weight lifting). It develops due to an inadequate closure mechanism of the urethral sphincter which cannot resist increased intra-abdominal pressure. • Urge urinary incontinence (UUI) Related to an urgent and irresistible desire to pass urine, which results in involuntary leakages of urine. UUI develops as a consequence of nervous dysregulation (overactive bladder (OAB))

Treatments for incontinence range from simple behavioral training exercises to drugs and surgery. Usually drugs used include antibiotics, anticholinergic drugs, and estrogen which in most cases exhibit some undesirable side effects. For example, some studies shown estrogens may increase the risk of endometrial carcinoma, may cause elevated blood pressure, increase the risk of gallbladder disease and other undesirable effects4.

DROPSORDRYTM supplementation is an effective strategy for UI

Fig, 1. Prevalences of different types of UI by age and severity3. Minassian. Urinary Incontinence in Women. Obstet Gynecol 2008.

1Luo, X., et al. International journal of clinical practice. 69.12 (2015): 1517-1524.; 2Turgut. A, et al. Acta medica mediterranea 30.4 (2014): 907-916; 3V.A. Minassian, et al.

Obstetrics & Gynecology 111.2, Part 1 (2008): 324-33; 4Gibson, D A. et al. Endocrine-related cancer 21.2 (2014): T13-T31;

Daily panty-liners1

CLINICAL STUDIES

BENFEFITS OF DROPSORDRY SUPPLEMENTATION

DURING MENOPAUSE AND PERI-MENOPAUSE IN

EUROPEAN WOMEN

Nocturnal urinary frequency2,4

Urge urinary incontinence

(UUI)3 Stress urinary incontinence

(SUI)1

0

0,5

1

1,5

2

2,5

3

0 week 4 week 8 week

Frequency

0

0,5

1

1,5

2

0 week 4 week 8 week

Frequency

0

0,2

0,4

0,6

0,8

0 week 4 week 8 week

Frequency

0

0,5

1

1,5

0 week 4 week 8 week

Frequency

66% 69%

46% 52%

0 week 4 week 8 week

2x500mg 1x500mg

96% of women refers a relief in urinary incontinence symptoms(n=82)3

1Marañón, J., et al. (2016). Efficacy of Dropsordy™ supplementation on urinary incontinence in perimenopause. Gynecological Endocrinology, 32:sup1, 1-189. 17th

World Congress of Gynecological Endocrinology. Firenze, Italy, March 2-5, 2016. 2Marañón, J., et al. (2016). Dropsordry™ decreases nighttime urinary episodes in women. Clinical study. Planta Med 2016; 82 - PB35 3Marañón, J., et al. (2016). Clinical Efficacy and Tolerability of Dropsordry™ in Spanish Perimenopausal Women With Urgency Urinary Incontinence (uui). 18th

International Conference on Obstetrics and Gynaecology. London, United Kingdom, February 25 - 26, 2016. 4Marañón, J., et al. (2016). Dropsordry supplementation decreases nighttime urinary episodes in perimenopause with Urinary Incontinence. Clinical study. 24th

EBCOG European congress of obstetrics and gynaecology. Torino, Italy, on May 19th – 21th 2016.

Relief in incontinence

symptoms

80,8%

7,7% 11,5%

Very satisfied Satisfied Dissatisfied

84,6%

7,7% 7,7%

96,2%

3,8%

92,4%

7,6%

Satisfaction with

incontinence after 8 weeks Effectiveness

Improvement of quality of

life

Patients would continue with

supplement

96%

4%

CLINICAL STUDIES

1Marañón, J., et al. (2016). Clinical Efficacy and Tolerability of Dropsordry™ in Spanish Perimenopausal Women With Urgency Urinary Incontinence (uui). 18th

International Conference on Obstetrics and Gynaecology. London, United Kingdom, February 25 - 26, 2016. 2Marañón, J., et al. (2016). Efficacy of Dropsordy™ supplementation on urinary incontinence in perimenopause. Gynecological Endocrinology, 32:sup1, 1-189. 17th

World Congress of Gynecological Endocrinology. Firenze, Italy, March 2-5, 2016.

ICIQ-SF QUESTIONNAIRE1-2

No side effects

92,3%

7,7%

YES NO

ABOUT - Proprietary blend of botanicals from SOLGEN soybean

isoflavones and Cucurbita pepo.

- Contains high levels of genistin & genistein isoflavones,

the phytoestrogen that favorably contributes in menopause

urinary incontinence1

- Genistein therapy regressed the degenerative changes

associated at OAB symptoms1

- Proprietary clinical studies in European women2-4

- 2 x 500mg for the first 4 weeks.

- 1 x 500mg for the following 20 weeks.

DOSAGE

WHY - 73% reduction of urine leakages3

- 46% reduction of Urge urinary incontinence episodes2

- 52% reduction of stress incontinence episodes (SUI)3

- 69% reduction in nocturia4,5

- 60% reduction in volume of nocturnal diuresis4

- 66% of reduction in daily panty-liners3

- GMP manufacturing (TRADICHEM INDUSTRIAL SERVICES)

“92% OF THE WOMEN SUBJECT OF THE STUDY REFERS AND

OVERALL IMPROVEMENT IN THE QUALITY OF LIFE”

DROPSORDRY IN BRIEF

1Turgut, A, et al. Acta Medica Mediterranea 30.4 (2014): 907-916; 2Marañón, J., et al. 18th International Conference on Obstetrics and Gynaecology. London, United

Kingdom, February 25 - 26, 2016; 3Marañón, J., et al. Gynecological Endocrinology, 32:sup1, 1-189. 17th World Congress of Gynecological Endocrinology. Firenze, Italy,

March 2-5, 2016; 4Marañón, J., et al. Planta Med 2016; 82 - PB35; 5Marañón, J., et al. (2016). 24th EBCOG European congress of obstetrics and gynaecology. Torino,

Italy, on May 19th – 21th 2016.

www.tradichem.es http://dropsordry.com